

ASX Release

Appointment of Dr Debora Barton as Non-Executive Director

PERTH, AUSTRALIA – 10 August 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, has appointed Dr Debora Barton, MD, as an independent Non-Executive Director.

Dr Barton has over 20 years' experience in the field of oncology. After practicing oncology as a physician and clinical trial investigator, she spent five years at Novartis and five years at Celgene in roles of increasing responsibilities in Medical Affairs and Clinical Development. Dr Barton has extensive experience working with cell therapy products, formerly as the Senior Vice President, Clinical and Head of Safety, of the clinical stage company, lovance, who are developing T cell therapies for cancer treatment. Dr Barton is currently the Chief Medical Officer of Carisma Therapeutics, a clinical stage biopharmaceutical company, developing innovative immunotherapies including the first in class chimeric antigen receptor (CAR) macrophages for the treatment of certain cancers.

Dr Barton is a member of the Manhattan Board of Directors for the American Cancer Society and is also a member of the Medical Advisory Board of the Tigerlily Foundation, a national breast cancer foundation providing education, awareness, advocacy and hands-on support to young women before, during and after breast cancer.

Commenting on her appointment, Dr Barton said, "I am very excited to be joining SUDA's Board of Directors, at what no doubt is an important step in the company's history. I look forward to supporting the team in developing the iNKT cell therapy platform and sharing the experience that I have acquired working with cell therapies and other innovative oncology products over the years."

Chief Executive Officer and Managing Director, Dr Michael Baker, commented, "We are delighted that someone with a track record like Debora's will be a part of our group at SUDA. She has a phenomenal amount of experience in developing oncology products across a range of areas, and most recently cell therapies. Her experience will add an important dimension to our board as we progress toward clinical trials."

For and on behalf of the Board and for further information, please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a biotechnology company focused on developing therapies to treat human disease. SUDA's two focus areas are oncology and conditions that impact the central nervous system. SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit www.sudapharma.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.